The effect of bisphosphonates on the risk of endometrial and ovarian malignancies.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Gynecologic Oncology

• Publication date

  2014-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ygyno.2014.02.014PMID 24556062
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Reduced risk of colorectal cancer with use of oral bisphosphonates: a systematic review and meta-analysis.

  2013cited by this paper
• Abstract P3-06-03: Oral bisphosphonates and survival of breast and colon malignancies

  2013cited by this paper
• Oral bisphosphonate use and colorectal cancer incidence in the Women's Health Initiative

  2013cited by this paper
• The effect of statins on risk and survival of gynecological malignancies.

  2013cited by this paper
• Beyond aspirin—cancer prevention with statins, metformin and bisphosphonates

  2013cited by this paper
• Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate—Danish National Register Based Cohort Study

  2012cited by this paper
• Bisphosphonate use and the risk of breast cancer: a meta-analysis of published literature.

  2012cited by this paper
• Exposure to oral bisphosphonates and risk of cancer

  2012cited by this paper
• Oral alendronate use and risk of cancer in postmenopausal women with osteoporosis: A nationwide study

  2012cited by this paper
• A prospective study of bisphosphonate use and risk of colorectal cancer.

  2012cited by this paper
• Exposure to bisphosphonates and risk of colorectal cancer

  2012cited by this paper
• Use of bisphosphonates and reduced risk of colorectal cancer.

  2011cited by this paper
• Bisphosphonate use after estrogen receptor-positive breast cancer and risk of contralateral breast cancer.

  2011cited by this paper
• Bisphosphonates: beyond prevention of bone metastases.

  2011cited by this paper
• Oral bisphosphonate use and breast cancer incidence in postmenopausal women.

  2010cited by this paper
• Enhancing cytotoxic and apoptotic effect in OVCAR-3 and MDAH-2774 cells with all-trans retinoic acid and zoledronic acid: a paradigm of synergistic molecular targeting treatment for ovarian cancer

  2010cited by this paper
• Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort.

  2010cited by this paper
• Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk

  2010cited by this paper
• Exposure to oral bisphosphonates and risk of esophageal cancer.

  2010cited by this paper
• Use of bisphosphonates and risk of postmenopausal breast cancer.

  2009cited by this paper
• Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay

  2009cited by this paper
• Statin use and female reproductive organ cancer risk in a large population-based setting

  2009cited by this paper
• Combined gossypol and zoledronic acid treatment results in synergistic induction of cell death and regulates angiogenic molecules in ovarian cancer cells.

  2009cited by this paper
• Validity and Reproducibility of a Semi-Quantitative Food Frequency Questionnaire Adapted to an Israeli Population

  2008cited by this paper
• Inhibitory effects of bisphosphonates on the proliferation of human ovarian cancer cell lines and the mechanism.

  2006cited by this paper
• Statins and the risk of colorectal cancer.

  2005cited by this paper
• Alendronate inhibits intraperitoneal dissemination in in vivo ovarian cancer model.

  2005cited by this paper
• Statin use and cancer risk in the General Practice Research Database

  2004cited by this paper
• Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of rho.

  2002cited by this paper
• 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study.

  2000cited by this paper
• Aspirin and the risk of colorectal cancer in women.

  1995cited by this paper

• Drug repurposing in gynaecological cancers: Proven drugs for new challenges.

  2025cites this paper
• Potential Benefits of Adding Alendronate, Celecoxib, Itraconazole, Ramelteon, and Simvastatin to Endometrial Cancer Treatment: The EC5 Regimen

  2025cites this paper
• Drug Repositioning for Ovarian Cancer Treatment: An Update.

  2024cites this paper
• Bisphosphonates: The role of chemistry in understanding their biological actions and structure-activity relationships, and new directions for their therapeutic use.

  2021cites this paper
• Endometrial cancer

  2021cites this paper
• Bisphosphonates pharmacology and use in the treatment of osteoporosis

  2021cites this paper
• Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer

  2020cites this paper
• Efficient catalyst free green synthesis and in vitro antimicrobial, antioxidant and molecular docking studies of α-substituted aromatic/heteroaromatic aminomethylene bisphosphonates

  2020cites this paper
• Recycling the Purpose of Old Drugs to Treat Ovarian Cancer

  2020cites this paper
• Bisphosphonates and risk of cancers: a systematic review and meta-analysis

  2020cites this paper
• ’ s response to reviews Title : Statin use and the risk of ovarian and endometrial cancers : A meta-analysis

  2019cites this paper
• ADP-ribosylation factor-like 4C predicts worse prognosis in endometriosis-associated ovarian cancers

  2019cites this paper
• Oral bisphosphonate use and the risk of female breast, ovarian, and cervical cancer: a nationwide population-based cohort study

  2019cites this paper
• Statin use and the risk of ovarian and endometrial cancers: a meta-analysis

  2019cites this paper
• Evaluation of the mevalonate pathway as a target for the treatment of ovarian cancer

  2018cites this paper
• Impact of postdiagnostic statin use on ovarian cancer mortality: A systematic review and meta‐analysis of observational studies

  2018cites this paper
• Statin Use Prior to Diagnosis Predicts High Risk Features in Early Stage Endometrioid Endometrial Cancer

  2018cites this paper
• Prognostic Effect of Bisphosphonate Exposure for Patients With Diagnosed Solid Cancer: A Systematic Review With Meta-Analysis of Observational Studies

  2018cites this paper
• Statin therapy and association with ovarian cancer risk in the New England Case Control (NEC) study

  2018cites this paper
• Risk reduction of endometrial and ovarian cancer after bisphosphonates use: A meta-analysis.

  2018cites this paper
• Oral bisphosphonate use and lung cancer incidence among postmenopausal women

  2018cites this paper
• Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians.

  2017cites this paper
• Inhibition of the mevalonate pathway augments the activity of pitavastatin against ovarian cancer cells

  2017cites this paper
• Risk-Reducing (Chemopreventive) Agents in Breast Cancer Prevention

  2016cites this paper
• Physiologic Activity of Bisphosphonates – Recent Advances

  2016cites this paper
• Bisphosphonate use and the risk of endometrial cancer: a meta‐analysis of observational studies

  2016cites this paper
• Orale Bisphosphonate senken möglicherweise die Inzidenz

  2015cites this paper
• Is Endometrial Cancer Risk Reduced by Oral Bisphosphonate Use?

  2015cites this paper
• Orale Bisphosphonate senken möglicherweise die Inzidenz von postmenopausalen Korpuskarzinomen

  2015cites this paper
• Oral bisphosphonate use and risk of postmenopausal endometrial cancer.

  2015cites this paper